Literature DB >> 28260912

Association of uremic pruritus in hemodialysis patients with the number of days of high mean 24-hour particulate matter with a diameter of <2.5 μm.

Ming-Hui Liu1, Ming-Jen Chan2, Ching-Wei Hsu3, Cheng-Hao Weng3, Tzung-Hai Yen3, Wen-Hung Huang3.   

Abstract

Uremic pruritus (UP) is a common and incapacitating symptom in patients undergoing hemodialysis (HD). The pathogenesis of UP is multifactorial and complex. Particulate matter (PM), a major air pollutant, is a mixture of particles with various chemical compositions. PM is associated with several allergic diseases, including dermatitis. To assess the role of PM (PM with a diameter of <10 μm [PM10] and PM with a diameter of <2.5 μm [PM2.5]) and other clinical variables in UP in patients on HD, we recruited 866 patients on maintenance HD (MHD). We analyzed the number of days of mean 24-hour PM10 ≥125 μg/m3/12 months (NDPM10) or the number of days of mean 24-hour PM2.5 ≥35 μg/m3/12 months (NDPM2.5) exceeding the standard level in the past 12 months respectively to determine the association with UP. In a multivariate logistic regression, HD duration, serum ferritin levels, low-density lipoprotein (LDL) levels, and NDPM2.5 ≥116 days/12 months were positively associated with UP. This cross-sectional study showed that the number of days on which the environmental PM2.5 exceeds the standard level might be associated with UP in patients on MHD.

Entities:  

Keywords:  PM2.5; air pollution; environmental particulate matter; uremic pruritus

Year:  2017        PMID: 28260912      PMCID: PMC5328135          DOI: 10.2147/TCRM.S129133

Source DB:  PubMed          Journal:  Ther Clin Risk Manag        ISSN: 1176-6336            Impact factor:   2.423


Introduction

Uremic pruritus (UP) is a common and disabling symptom in hemodialysis (HD) patients. The prevalence of UP varies from 22% to 90%.1–3 To date, the pathogenesis of UP is considered multifactorial and remains poorly understood.4–7 Dermatological abnormalities, systemic inflammation, an imbalance of the endogenous opioidergic system, and a neuropathic mechanism are considered the main hypotheses.8 Particulate matter (PM), a major air pollutant, is a mixture of particles with various chemical compositions. PM is classified according to its size as follows: PM with a diameter of <10 μm (PM10), PM with a diameter of <2.5 μm (PM2.5), and PM with a diameter of <0.1 μm (ultrafine particles [UFPs]). Previous studies have reported that PM is associated with allergic diseases such as asthma,9–11 allergic rhinitis,12 and dermatitis.13,14 However, to our knowledge, a detailed study on the correlation between PM and UP in patients on maintenance HD (MHD) has not been reported. Therefore, the present cross-sectional study was conducted to assess the association between environmental PM (PM2.5 and PM10) and UP in patients on MHD.

Patients and methods

Methods

This cross-sectional study was approved by the medical ethics committee of Chang Gung Memorial Hospital. Written informed consent was obtained from all patients for this study. All patient information was kept confidential and made available only to the investigators. All medical records during the study period, including medical history, laboratory data, and inclusion and exclusion factors, were reviewed by senior nephrologists who have the experiences in experimental protocal. Furthermore, all experimental protocols were conducted in accordance with the guidelines of Strengthening the Reporting of Observational Studies in Epidemiology.

Study population

Patients were recruited from the three HD centers of the Chang Gung Memorial Hospital and the Taipei and Taoyuan branches of the Linkou Medical Center. Only patients on MHD who were aged ≥18 years and had undergone HD for at least 6 months were enrolled in this study. Patients with malignancies or obvious infectious diseases and patients who had been hospitalized or had undergone surgery within 3 months prior to the investigation were excluded. Diabetes mellitus (DM) was defined by either a physician’s diagnosis and antidiabetic drug treatment or two subsequent analyses demonstrating fasting blood glucose levels of >126 mg/dL. HD was performed using single-use hollow-fiber dialyzers equipped with modified cellulose, polyamide, or polysulfone membranes. The dialysate used in all cases had a standard ionic composition with a bicarbonate-based buffer. Patients undergoing hemodiafiltration (HDF) thrice weekly for ≥3 months were also included. We noted the incidence of cardiovascular disease (CVD), including cerebrovascular disease, coronary artery disease, congestive heart failure, and peripheral vascular disease, in these patients. Hypertension was defined by the regular use of antihypertensive drugs to control blood pressure or at least two blood pressure measurements >140/90 mmHg. Smoking behavior was also noted. Pruritus was screened from our HD centers. The diagnosis of pruritus was as follows: pruritus appearing after HD with or without antipruritics as observed by trained dermatologists or nephrologists. (The pruritus may be constant or intermittent and commonly associated with xerosis. There is a scratch with no primary lesions, and the back is the most commonly affected area. However, arms, head, and abdomen are also commonly affected.) The intensity of pruritus was measured by a visual analog scale (VAS), which consisted of a 10-cm horizontal line with 0 points (no pruritus) to 10 points (maximum intensity of pruritus). Individual exposure to PM2.5 or PM10 was estimated using a geographic information system of the Taiwan Air Quality Monitoring Network, which is operated by the Environmental Protection Administration15 to determine the mean previous 12-month concentrations of PM2.5 and PM10 in patients’ living areas. The number of days on which the concentrations of PM2.5 or PM10 exceeded the standard mean 24-hour concentrations during the previous 12 months was calculated, with standard levels defined as <35 and <125 μg/m3, respectively.15

Laboratory, nutritional, and inflammatory parameters

All blood samples were drawn from the arterial end of the vascular access immediately after the initial 2-day interval before HD; the samples were then centrifuged and stored at −80°C until use. Nutritional markers such as serum creatinine levels, normalized protein catabolic rate (nPCR), and serum albumin levels were assayed and recorded. The nPCRs of the studied patients were calculated using validated equations and were normalized to their respective body weights.16 High-sensitivity C-reactive protein (hsCRP) levels were measured as indices of inflammation. A standard laboratory approach with an automatic analyzer was used for all other biochemical tests. Dialyzer clearance of urea (Kt/Vurea) was measured using a method described by Daugirdas.17 The serum calcium level was corrected with the serum albumin level. Anuria was defined as a daily urine amount of <100 mL.

Statistical analysis

Continuous variables (normal and nonnormal distributions) were expressed as mean ± standard deviation or median (interquartile range). Categorical variables were expressed as frequency or percentage. A χ2 test or Fisher’s exact test was used to analyze the correlation between categorical variables. Comparisons between two groups were performed using the Mann–Whitney U test or Student’s t-test. The Kolmogorov–Smirnov test was used to test whether the variables were normally distributed. To assume a normal distribution, P>0.05 was required. According to nonnormal distribution data, hsCRP, intact parathyroid hormone (iPTH), and ferritin levels were log transformed for analysis. Discrimination was assessed through an area under the receiver operating characteristic (AUROC) analysis, which was also used to calculate the cutoff values, sensitivity, specificity, and overall correctness. Finally, the optimal cutoff points were calculated by acquiring the maximum value of the Youden index (sensitivity + specificity − 1). To evaluate the relationship with UP, univariate and multivariate (forward method) logistic regression analyses were performed to assess the odds ratios (ORs) and 95% confidence intervals (CIs) for the baseline variables, including age, male sex, body mass index (BMI), smoking status, DM, hypertension, previous CVD, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, HD duration, blood access fistula, HDF, Kt/Vurea, nPCR, nonanuria status, hemoglobin level, serum albumin level, serum creatinine level, corrected calcium level, inorganic phosphate level, log ferritin level, log iPTH level, log hsCRP level, low-density lipoprotein (LDL) level, triglyceride level, the number of days of mean 24-hour PM2.5 ≥35 μg/m3/12 months (NDPM2.5), and the number of days of mean 24-hour PM10 ≥125 μg/m3/12 months (NDPM10). According to the low collinearity (variance inflation factor; NDPM2.5 ≥116 days/12 months, 1.75; NDPM10 ≥4.5 days/12 months, 1.74), in Analysis C, we included the two aforementioned items together for a multivariate logistic regression analysis. All nominal variables in the logistic regression were transformed into dummy variables. Missing data were approached using list-wise deletion. Data were analyzed using SPSS version 12.0 for Windows (IBM Corp., Armonk, NY, USA). The level of significance was set at P<0.05.

Results

In total, 866 patients on MHD were included in the study. Table 1 lists the patient characteristics, including comorbidities; dialysis-related data along with related biological and hematological information; and information regarding PM exposure for all patients with or without UP. There were 189 patients with UP. The median of VAS was 6. The correlation between NDPM2.5 ≥116 days/12 months (r=0.06, P=0.37), NDPM10 ≥4.5 days/12 months (r=0.08, P=0.27), and VAS was not significant.
Table 1

Characteristics of studied patients on MHD with/without UP

CharacteristicsTotal (866), mean ± SD/median (IR)Without pruritus (677), mean ± SD/median (IR)With pruritus (189), mean ± SD/median (IR)P-value
Demographics
 Age (years)56.18±13.5955.70±13.8657.93±12.430.046
 Male sex (yes)440 (50.8%)352 (52%)88 (46.6%)0.181
 Body mass index (kg/m2)22.19±3.1822.23±3.1322.06±3.370.522
 Smoking (yes)150 (17.3%)120 (17.7%)30 (15.9%)0.581
Comorbidity
 DM (yes)192 (22.2%)167 (24.7%)25 (13.2%)0.001
 Hypertension (yes)339 (39.1%)266 (39.3%)73 (38.6%)0.932
 Previous CVD (yes)41 (4.7%)34 (5%)7 (3.7%)0.561
 HBV (yes)98 (11.3%)84 (12.4%)14 (7.4%)0.063
 HCV (yes)168 (19.4%)121 (17.9%)47 (24.9%)0.037
Dialysis-related data
 Hemodialysis duration (yes)6.96±5.356.27±5.139.41±5.43<0.001
 Erythropoietin (U/kg/week)73.62±47.3775.06±47.7168.45±45.870.097
 Fistula as blood access (yes)689 (79.6%)532 (78.6%)157 (83.1%)0.182
 Hemodiafiltration (yes)187 (21.6%)135 (19.9%)52 (27.5%)0.028
Kt/Vurea1.79±0.321.77±0.321.89±0.34<0.001
 nPCR (g/kg/day)1.18±0.261.17±0.261.22±0.270.034
 Residual daily urine of >100 m178 (20.6%)156 (23%)22 (11.6%)<0.001
Biochemical data
 Hemoglobin (g/dL)10.51±1.3610.48±1.3410.62±1.450.204
 Albumin (g/dL)4.06±0.344.07±0.344.01±0.330.019
 Creatinine (mg/dL)10.88±2.3910.90±2.4210.84±2.290.744
 Ferritin (μg/L)*305.0 (129.57, 504.45)296 (116.60, 505.41)335.2 (189.20, 499.40)0.133
 Corrected-calcium (mg/dL)9.94±0.939.91±0.9110.05±0.970.055
 Phosphate (mg/dL)4.84±1.354.84±1.334.84±1.410.991
 iPTH (pg/mL)*130.1 (52.52, 319.2)121.3 (47.7, 284.1)187.2 (63.8, 401.7)0.003
 hsCRP (mg/L)*2.95 (1.4, 7.01)2.89 (1.38,7.39)3.04 (1.43,5.94)0.872
Cardiovascular risks
 Cholesterol (mg/dL)171.3±37.66169.73±37.08176.93±39.240.021
 Triglyceride (mg/dL)164.33±115.8167.11±118.67154.36±104.570.183
 LDL (mg/dL)94.83±30.5993.26±30.30100.36±31.050.005
 Mean previous 12-month PM10 concentration51.54±7.6551.85±7.7450.46±7.210.285
 Mean previous 12-month PM2.5 concentration28.57±3.6628.45±3.6129.01±3.820.001
 NDPM10 (days)4 (2, 5)4 (2, 5)4 (3, 5)0.5
 NDPM2.5 (days)115 (102, 118)113 (100, 115)117 (102, 118)<0.001

Note:

Non-normal distribution data are presented as median (IR).

Abbreviations: MHD, maintenance hemodialysis; UP, uremic pruritus; SD, standard deviation; IR, interquartile range; DM, diabetes mellitus; CVD, cardiovascular disease; HBV, hepatitis B virus; HCV, hepatitis C virus; Kt/Vurea, dialysis clearance of urea; nPCR, normalized protein catabolic rate; iPTH, intact parathyroid hormone; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; PM10, particulate matter with a diameter of <10 μm; PM2.5, particulate matter with a diameter of <2.5 μm; NDPM10, the number of days of mean 24-hour PM10 ≥125 μg/m3/12 months; NDPM2.5, the number of days of mean 24-hour PM2.5 ≥35 μg/m3/12 months.

Comparison of clinical variables between patients with and without UP

A comparison of the patients with and without UP revealed that a higher proportion of those with UP had HCV infection and had undergone HDF, whereas a lower proportion of them had DM and a nonanuria condition. Moreover, patients with UP were older than those without UP. Furthermore, patients with UP had longer HD durations; had higher Kt/Vurea, nPCR, iPTH, cholesterol, and LDL levels; and had lower serum albumin levels than those without UP (Table 1).

AUROC for NDPM2.5 and NDPM10

A higher NDPM2.5 was associated with UP. Computation of the AUROC confirmed that NDPM2.5 had favorable discriminatory power (AUROC =0.591±0.025; 95% CI, 0.54–0.64; P<0.001; Figure 1). The optimal cutoff point for NDPM2.5 was 116 days/12 months (sensitivity, 51%; specificity, 78%; overall correctness, 72.4%; Table 2). Similarly, the AUROC confirmed that NDPM10 had favorable discriminatory power (AUROC =0.564±0.024; 95% CI, 0.51–0.61; P=0.007; Figure 2). The optimal cutoff point for NDPM10 was 4.5 days/12 months (sensitivity, 48%; specificity, 74%; overall correctness, 68.6%; Table 2). These optimal cutoff points were used in the univariate and multivariate binary logistic regression analyses to evaluate their association with UP.
Figure 1

Computation of the AUROC confirmed favorable discriminatory power of NDPM2.5 (AUROC =0.591±0.025; 95% CI, 0.54–0.64; P<0.001).

Notes: The optimal cutoff point for NDPM2.5 derived from the maximal value of the Youden index, was 116 days/12 months (sensitivity, 51%; specificity, 78%). Green line represents reference line. Blue line represents NDPM2.5.

Abbreviations: ROC, receiver operating characteristic; AUROC, area under the receiver operating characteristic; NDPM2.5, the number of days of mean 24-hour PM2.5 ≥35 μg/m3/12 months; CI, confidence interval; PM2.5, particulate matter with a diameter of <2.5 μm.

Table 2

Prediction of pruritus by NDPM2.5 and NDPM10

Predictive factorsCutoff pointYouden indexSensitivity (%)Specificity (%)Overall correctness (%)
NDPM2.5, days1160.29517872.4
NDPM10, days4.50.22487468.6

Abbreviations: NDPM2.5, the number of days of mean 24-hour PM2.5 ≥35 µg/m3/12 months; NDPM10, the number of days of mean 24-hour PM10 ≥125 µg/m3/12 months; PM2.5, particulate matter with a diameter of <2.5 µm; PM10, particulate matter with a diameter of <10 µm

Figure 2

Computation of the AUROC confirmed favorable discriminatory power of NDPM10 (AUROC =0.564±0.024; 95% CI, 0.51–0.61; P=0.007).

Notes: The optimal cutoff point for NDPM10, derived from the maximal value of the Youden index, was 4.5 days/12 months (sensitivity, 48%; specificity, 74%). Green line represents reference line. Blue line represents NDPM10.

Abbreviations: AUROC, area under the receiver operating characteristic; CI, confidence interval; NDPM10, the number of days of mean 24-hour PM10 ≥125 μg/m3/12 months; PM10, particulate matter with a diameter of <10 μm.

Associations between UP and clinical variables

Univariate logistic regression identified several clinical variables that were significantly associated with UP (Table 3), such as BMI, DM, HCV infection, HD duration, HDF, Kt/Vurea, nPCR, nonanuria status, serum albumin level, log iPTH level, LDL level, and the optimal cutoff points for NDPM2.5 and NDPM10. To determine the association between UP and the number of days on which the mean 24-hour PM levels were greater than the standard values (NDPM2.5 ≥116 days/12 months and NDPM10 ≥4.5 days/12 months), multivariate forward logistic regression analysis of variables with P<0.1 in the univariate logistic regression was performed in three models (Analysis A: including the optimal cutoff point for NDPM2.5, Analysis B: including the optimal cutoff point for NDPM10, and Analysis C: including the optimal cutoff points for NDPM2.5 and NDPM10). The results of Analysis A indicated that HD duration (OR, 1.11; 95% CI, 1.08–1.15; P<0.001), log ferritin level (OR, 1.72; 95% CI, 1.16–2.55; P=0.007), LDL level (OR, 1.01; 95% CI, 1.00–1.01; P=0.006), and the optimal cutoff point for NDPM2.5 (OR, 3.57; 95% CI, 2.50–5.10; P<0.001) were associated with UP (Table 4). The results of analysis B indicated that HD duration (OR, 1.12; 95% CI, 1.08–1.15; P<0.001), serum albumin level (OR, 0.57; 95% CI, 0.34–0.95; P=0.032), log ferritin level (OR, 1.66; 95% CI, 1.13–2.45; P=0.01), LDL level (OR, 1.01; 95% CI, 1.00–1.01; P=0.006), and the optimal cutoff point for NDPM10 (OR, 2.54; 95% CI, 1.78–3.62; P<0.001) were associated with UP (Table 4). The results of analysis C indicated that HD duration (OR, 1.11; 95% CI, 1.08–1.15; P<0.001), log ferritin level (OR, 1.72; 95% CI, 1.16–2.55; P=0.007), LDL level (OR, 1.01; 95% CI, 1.00–1.01; P=0.006), and the optimal cutoff point for NDPM2.5 (OR, 3.57; 95% CI, 2.50–5.10; P<0.001) were associated with UP (Table 5).
Table 3

Univariate logistic regression analysis between UP and clinical variables

Characteristics
Univariate logistic regression
P-value
VariablesOR (95% CI)
Body mass index (kg/m2)1.07 (1.01–1.15)0.036
DM (yes)0.46 (0.29–0.73)0.001
HBV (yes)0.56 (0.31–1.01)0.058
HCV (yes)1.52 (1.03–2.23)0.032
Hemodialysis duration (years)1.11 (1.05–1.15)<0.001
Hemodiafiltration (yes)1.52 (1.05–2.20)0.026
Kt/Vurea2.94 (1.8–4.79)<0.001
nPCR (g/kg/day)1.93 (1.06–3.51)0.03
Nonanuria0.44 (0.27–0.71)0.001
Serum albumin (g/dL)0.57 (0.36–0.91)0.02
Corrected calcium (mg/dL)1.18 (0.99–1.40)0.056
Log ferritin1.37 (0.96–1.95)0.079
Log iPTH1.52 (1.14–2.02)0.004
Cholesterol (mg/dL)1.01 (1.00–1.01)0.021
LDL (mg/dL)1.01 (1.00–1.01)0.005
NDPM2.5 ≥116 days (yes)3.75 (2.67–5.26)<0.001
NDPM10 ≥4.5 days (yes)2.64 (1.89–3.69)<0.001

Notes: P>0.1, not presented in table including age, male sex, smoking, hypertension, previous CVD, fistula as blood access, hemoglobin, creatinine, phosphate, log hsCRP, and triglyceride.

Abbreviations: UP, uremic pruritus; OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; Kt/Vurea, dialysis clearance of urea; nPCR, normalized protein catabolic rate; iPTH, intact parathyroid hormone; LDL, low-density lipoprotein; NDPM2.5, the number of days of mean 24-hour PM2.5 ≥35 μg/m3/12 months; NDPM10, the number of days of mean 24-hour PM10 ≥125 μg/m3/12 months; PM2.5, particulate matter with a diameter of <2.5 μm; PM10, particulate matter with a diameter of <10 μm; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; log, logarithm.

Table 4

Multivariate logistic regression analysis (forward method) between UP and NDPM2.5 ≥116 days/12 months, NDPM10 ≥4.5 days/12 months, and other variables (P<0.1 in univariate logistic regression)

#VariablesAnalysis A: multivariate logistic regression (excluding NDPM10 ≥4.5 days/12 months)
P-valueAnalysis B: multivariate logistic regression (excluding NDPM2.5 ≥116 days/12 months)
P-value
OR (95% CI)OR (95% CI)
Hemodialysis duration (years)1.11 (1.08–1.15)<0.0011.12 (1.08–1.15)<0.001
Serum albumin (g/dL)0.57 (0.34–0.95)0.032
Log ferritin1.72 (1.16–2.55)0.0071.66 (1.13–2.45)0.010
LDL (mg/dL)1.01 (1.00–1.01)0.0061.01 (1.00–1.01)0.003
NDPM2.5 ≥116 days/12 months (yes)3.57 (2.50–5.10)<0.001
NDPM10 ≥4.5 days/12 months (yes)2.54 (1.78–3.62)<0.001

Notes:

After adjustment for body mass index, DM, HBV, HCV, hemodiafiltration, Kt/Vurea, nPCR, nonanuria, corrected calcium, and log iPTH. ‘–’ represents not significance.

Abbreviations: UP, uremic pruritus; NDPM2.5, the number of days of mean 24-hour PM2.5 ≥35 μg/m3/12 months; NDPM10, the number of days of mean 24-hour PM10 ≥125 μg/m3/12 months; OR, odds ratio; CI, confidence interval; LDL, low-density lipoprotein; DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; Kt/Vurea, dialysis clearance of urea; nPCR, normalized protein catabolic rate; iPTH, intact parathyroid hormone; PM2.5, particulate matter with a diameter of <2.5 μm; PM10, particulate matter with a diameter of <10 μm; log, logarithm.

Table 5

Multivariate logistic regression analysis (forward method) between UP and NDPM2.5 ≥116 days/12 months, NDPM10 ≥4.5 days/12 months, and other variables (P<0.1 in univariate logistic regression)

#VariablesAnalysis C: multivariate logistic regression
P-value
OR (95% CI)
Hemodialysis duration (years)1.11 (1.08–1.15)<0.001
Serum albumin (g/dL)
Log ferritin1.72 (1.16–2.55)0.007
LDL (mg/dL)1.01 (1.00–1.01)0.006
NDPM2.5 ≥116 days/12 months (yes)3.57 (2.50–5.10)<0.001
NDPM10 ≥4.5 days/12 months (yes)

Notes:

After adjustment for body mass index, DM, HBV, HCV, hemodiafiltration, Kt/Vurea, nPCR, nonanuria, corrected calcium, log iPTH, serum albumin, and NDPM10 ≥4.5 days/12 months. ‘–’ represents not significance.

Abbreviations: UP, uremic pruritus; NDPM2.5, the number of days of mean 24-hour PM2.5 ≥35 μg/m3/12 months; NDPM10, the number of days of mean 24-hour PM10 ≥125 μg/m3/12 months; OR, odds ratio; CI, confidence interval; LDL, low-density lipoprotein; DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; Kt/Vurea, dialysis clearance of urea; nPCR, normalized protein catabolic rate; iPTH, intact parathyroid hormone; PM2.5, particulate matter with a diameter of <2.5 μm; PM10, particulate matter with a diameter of <10 μm; log, logarithm.

Discussion

The results of the present cross-sectional study indicate that, after adjustment for related factors, the NDPM2.5 is a significant factor for UP in patients undergoing HD. The mechanism of UP is complex and not yet fully understood. A study on the cause–effect relationship between PM and skin lesions is difficult because of the method of data collection and analysis of PM. The mechanisms of UP are included under abnormalities of opioid receptors, proinflammatory states with a high level of particular cytokines, malnutrition, interface of the distal ends of unmyelinated C fibers with dermal mast cells,18–20 and skin barrier destruction inducing an increase in neuron-specific enolase-immunoreactive nerve fibers in the epidermis.21 Outdoor air pollution has been reported to affect the health of patients with allergic diseases, such as asthma, atopic dermatitis (AD), and conjunctivitis.22–25 To our knowledge, this study is the first to demonstrate that the NDPM2.5 ≥116 days is associated with UP in patients on MHD. PM is a mixture of solid and liquid particles of different origins. It includes metals, volatile organic compounds, bacteria, virus, airborne allergens, suspended atmospheric dust, soil, and smoke. PM is classified on the basis of size; for instance, PMs with diameters <10 μm, <2.5 μm, and ≤0.1 μm are called PM10, PM2.5, and UFPs, respectively. Patients may be exposed to PM mainly through inhalation, ingestion, and skin contact. In research on Asian dust and dermatitis, dermatitis was significantly associated with PM levels during an Asian dust event,26 and dust particle-bound metals (particularly nickel) were considered the cause of dermatitis.27 The use of a mobile detector, the Pre-toddler Inhalable Particulate Environmental Robot, to investigate the association between PM exposure and eczema among preschoolers showed an association between PM concentrations and eczema (OR, 2.85).28 In a 3-year observational study on PM10 and skin lesions in 9–11-year-old school children,13 the lifetime prevalence of AD (eczema) in 4,907 children was significantly associated with the 3-year mean concentrations of PM10 (OR, 1.13). However, in a worldwide study on the prevalence of ambient PM on allergic diseases including eczema, Anderson et al29 observed no significant association between PM10 and the prevalence of eczema in children. In a birth cohort study,30 infants with high prenatal exposure to PM2.5 in combination with postnatal exposure to environmental tobacco smoke were potentially at a higher risk of eczema in infancy (OR, 2.39). Kathuria and Silverberg31 also reported an association between PM2.5 and eczema. In a prospective study of symptoms of AD,14 outdoor PM2.5 and PM10 concentrations were higher on days when the patients had symptoms of AD. However, few studies have investigated the association between UFPs and skin lesions. In a study of 41 school children,32 pruritus scores were significantly associated with UFP concentrations. Because air quality constantly changes, the study of air pollutants on skin lesions is difficult. It is difficult to accurately estimate the concentration of an air pollutant during the exposure period. In studies on the association between PMs and skin lesion, the mean concentrations of PMs over hours,27,30,32–34 days,28,35,36 and years31 have been used for analysis. In several studies on the association between air pollution and allergic disease,22–25 the duration of observation is 12 months. Therefore, to calculate the concentration of PMs objectively, we used the daily mean PM concentrations of the previous 12 months for our analysis. In Analyses A and B (Table 4), the optimal cutoff points for NDPM2.5 (OR =3.57) and NDPM10 (OR =2.54) separately exhibited strong positive correlations with UP. However, in Analysis C, taken together in the analysis, the optimal cutoff point for NDPM2.5 correlated positively with UP with a high OR (3.57), whereas that for NDPM10 did not. This is the first study to suggest that daily mean PM exceeding the standard value is associated with UP. From relevant literature29–32 and the results of our study, the particle size of PM and the number of days of exposure to high concentrations of PMs appear to be risk factors for UP in patients on MHD. The role of PM in UP is unclear. As previously mentioned, inhalation and skin contact may be routes for UP in our patients on HD (this uncertainty is because of the lack of literature discussing PMs in drinking water or the surface of foods). Moreover, air pollutants are likely to aggravate symptoms, such as pruritus, possibly by inducing oxidative stress in the skin, which leads to skin barrier dysfunction, an increase in the number of neuronal fibers in the epidermis, immune dysregulation, or neurogenic inflammation.32,34,37–40 By demonstrating increased gene expression and transcription of the cytokines interleukin (IL)-6, IL-8, and granulocyte-macrophage colony-stimulating factor (GM-CSF), Choi et al41 showed that the inflammatory or proinflammatory reactions induced in response to Asian dust induced dermatitis; they also reported the effects of Asian dust on keratinocyte differentiation.

Conclusion

The results of the present cross-sectional study reveal that NDPM2.5 might be associated with UP in patients on MHD and that NDPM2.5 ≥116 days/12 months might be associated with the maximum probability of UP in this population. Furthermore, the prevalence of UP may differ by location. Further research is required in order to clarify the role of other air pollutants or environmental factors on UP in patients undergoing MHD.

Limitations

This study has some limitations. First, we did not include other factors such as humidity, seasons, temperature, diets, and mites or contact irritants. Therefore, we may have underestimated or overestimated the correlation between environmental PMs and UP. Second, this was a cross-sectional study. We observed only the correlation between environmental PM2.5 and UP and not the cause–effect relationship between them. The third limitation of this study is the assessment of how much and how often exposure occurs for a particular substance, which is difficult. Because of the difficulty on the activity of study population, objectively, we used the previous 12-month PM message around living areas for analysis.
  40 in total

1.  Symptoms of atopic dermatitis are influenced by outdoor air pollution.

Authors:  Jihyun Kim; Eun-Hye Kim; Inbo Oh; Kweon Jung; Youngshin Han; Hae-Kwan Cheong; Kangmo Ahn
Journal:  J Allergy Clin Immunol       Date:  2013-06-12       Impact factor: 10.793

2.  Adverse health effects of Asian dust particles and heavy metals in Japan.

Authors:  Kazunari Onishi; Shinji Otani; Atsushi Yoshida; Haosheng Mu; Youichi Kurozawa
Journal:  Asia Pac J Public Health       Date:  2012-08-02       Impact factor: 1.399

3.  Pruritus: control of itch in patients undergoing dialysis.

Authors:  M Mettang; E Weisshaar
Journal:  Skin Therapy Lett       Date:  2010-02

Review 4.  Allergic Rhinitis: Environmental Determinants.

Authors:  Joan Dunlop; Elizabeth Matsui; Hemant P Sharma
Journal:  Immunol Allergy Clin North Am       Date:  2016-03-10       Impact factor: 3.479

5.  Effects of prenatal and perinatal exposure to fine air pollutants and maternal fish consumption on the occurrence of infantile eczema.

Authors:  Wieslaw Jedrychowski; Frederica Perera; Umberto Maugeri; Dorota Mrozek-Budzyn; Rachel L Miller; Elzbieta Flak; Elzbieta Mroz; Ryszard Jacek; John D Spengler
Journal:  Int Arch Allergy Immunol       Date:  2011-02-03       Impact factor: 2.749

Review 6.  [Uremic pruritus--pathogenesis and treatment].

Authors:  Eli Johanne Nordal; Ingrid Os
Journal:  Tidsskr Nor Laegeforen       Date:  2007-05-03

7.  Residential proximity fine particles related to allergic sensitisation and asthma in primary school children.

Authors:  Isabella Annesi-Maesano; David Moreau; Denis Caillaud; François Lavaud; Yvon Le Moullec; André Taytard; Gabrielle Pauli; Denis Charpin
Journal:  Respir Med       Date:  2007-04-17       Impact factor: 3.415

Review 8.  [Uremic pruritus: an unresolved challenge].

Authors:  F Aucella; A Gesuete
Journal:  G Ital Nefrol       Date:  2009 Sep-Oct

9.  Intraepidermal neuron-specific enolase (NSE)-immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance hemodialysis.

Authors:  O Johansson; M Hilliges; M Ståhle-Bäckdahl
Journal:  Neurosci Lett       Date:  1989-05-08       Impact factor: 3.046

10.  Relationship between indoor air pollutant levels and residential environment in children with atopic dermatitis.

Authors:  Jung Hyun Lee; Ho Seok Lee; Mi Ran Park; Sang Woon Lee; Eun Hye Kim; Joong Bum Cho; Jihyun Kim; Youngshin Han; Kweon Jung; Hae Kwan Cheong; Sang Il Lee; Kangmo Ahn
Journal:  Allergy Asthma Immunol Res       Date:  2014-09-11       Impact factor: 5.764

View more
  6 in total

1.  Association Between Serum Aluminum Level and Uremic Pruritus in Hemodialysis Patients.

Authors:  Ching-Wei Hsu; Cheng-Hao Weng; Ming-Jen Chan; Dan-Tzu Lin-Tan; Tzung-Hai Yen; Wen-Hung Huang
Journal:  Sci Rep       Date:  2018-11-22       Impact factor: 4.379

2.  Short-term exposure to particulate matters is associated with septic emboli in infective endocarditis.

Authors:  Fu-Chien Hsieh; Chun-Yen Huang; Sheng-Feng Lin; Jen-Tang Sun; Tzung-Hai Yen; Chih-Chun Chang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Association of short-term exposure to ambient PM2.5 with hospital admissions and 30-day readmissions in end-stage renal disease patients: population-based retrospective cohort study.

Authors:  Lauren H Wyatt; Yuzhi Xi; Abhijit Kshirsagar; Qian Di; Cavin Ward-Caviness; Timothy J Wade; Wayne E Cascio; Ana G Rappold
Journal:  BMJ Open       Date:  2020-12-15       Impact factor: 2.692

4.  Determinants of the intensity of uremic pruritus in patients receiving maintenance hemodialysis: A cross-sectional study.

Authors:  Jian-Hui Zhao; Qiu-Shuang Zhu; Yi-Wen Li; Li-Li Wang
Journal:  PLoS One       Date:  2021-01-20       Impact factor: 3.240

5.  Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.

Authors:  Eriko Kinugasa; Ken Igawa; Hisaki Shimada; Morihiro Kondo; Satoshi Funakoshi; Naoki Imada; Noritomo Itami; Naoki Fukazawa; Ryoko Takubo; Yuichi Kawata; Hiroyuki Murota
Journal:  Clin Exp Nephrol       Date:  2021-03-22       Impact factor: 2.801

Review 6.  Chronic Kidney Disease-Associated Itch (CKD-aI) in Children-A Narrative Review.

Authors:  Radomir Reszke; Katarzyna Kiliś-Pstrusińska; Jacek C Szepietowski
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.